| Theme | Diagnosis and treatment for coronary artery disease and valvular heart disease in dialysis patients | |
|---|---|---|
| Title | Mitral valve surgery and anti-coagulant therapy for dialysis patients | |
| Publish Date | 2014/07 | |
| Author | Shinya Fukui | Department of Cardiovascular surgery, Hyogo College of Medicine |
| Author | Yuji Miyamoto | Department of Cardiovascular surgery, Hyogo College of Medicine |
| [ Summary ] | Dialysis patients may develop infections and bleeding from puncture sites and are likely to exhibit systemic calcification. When mitral valve surgery is performed on dialysis patients, it is still controversial whether it is better to use, mechanical or bioprosthetic valves. The same anti-coagulant therapy is required for dialysis patients receiving mechanical valves as for non-dialysis patients. Early failure and calcification of bioprosthetic valves has been reported. Mitral valve repair has become the gold standard therapy for patients with mitral regurgitation. Surgical and longterm outcomes for this procedure are excellent. Anti-coagulant therapy and concerns about calcification are not necessary for mitral valve repair. It is well known that cardiac function in patients having had mitral valve repair may be improved and maintained after surgery. Considering the advantages of mitral valve repair, it is thought to be suitable for dialysis patients having mitral regurgitation. |
|